|
|
- MHRA (Medicines) Drug Alerts (Various Recipients)
- Other contacts
- Specialists Trusts
- Independent Healthcare Providers (registered with CAS)
- Clinical Commissioning Groups
- NHS Foundation Trusts (England) - Medical Director
- NHS Foundation Trusts (England) - Chief Executive
- Ambulance Trusts
- Special Health Authorities
- NHS Trusts (England) - Medical Director
- CMO Urgent Messages - Non-NHS Recipients on Public Health Link
- MHRA (Medicines) Drug Alerts - Non-NHS Recipients
- Territorial CMOs in Northern Ireland, Scotland & Wales
- Regional Directors of Public Health
- Consultants in Communicable Diseases
- CMO Urgent Messages - Recipients on Public Health Link
- Director of Public Health
- Acute Trusts
- NHS Trusts (England) - Chief Executive
|
| Title: |
|
Treatment of Hospital-Onset COVID-19 in Adults and Children
|
| Broadcast content: |
|
The published UK-wide policy has been updated, effective with immediate effect, following consideration of the updated COVID therapeutic guideline from the World Health Organization (WHO), a review of the latest available evidence (including pharmacokinetic and pharmacodynamic data) and the extension to the marketing authorisation for remdesivir to cover adults and children (of all ages) weighing 40kg and above who do not require supplemental oxygen and who are at risk of progressing to severe COVID-19.
The updated policy revises the available treatment choices for eligible adults and children (weighing 40kg and above) admitted to hospital for a non-COVID reason, but who nonetheless test positive for COVID during their hospital stay. Treatments choices are now nirmatrelvir/ritonavir (Paxlovid) (first line), or remdesivir (second line). Exceptionally, sotrovimab may be considered where the available antiviral treatments are deemed to be unsuitable and its use is supported following multi-disciplinary team (MDT) assessment.
|
| Additional information: |
|
This alert is not relevant to Primary Care.
|